ISL1:小细胞肺癌中的一种新型神经内分泌亚型预测了对 Lurbinectedin 的持久反应
Misty D Shields1, Katherine G Minton1, Hilal Ozakinci2
1Indiana University School of Medicine Indianapolis, IN United States.
Molecular cancer therapeutics
|January 26, 2026
概括
研究人员确定ISL1作为一种新的生物标志物,预测小细胞肺癌 (SCLC) 中对lurbinectedin的反应. 这一发现可能会改善患有这种具有挑战性的胸部恶性瘤的患者的治疗选择.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 小细胞肺癌 (SCLC) 是一种高度侵略性的胸部恶性瘤,存活率低,化学抵抗性频繁.
- 卢比内克丁在SCLC患者的一个子集中显示出有效性,因此需要预测生物标志物来进行最佳治疗选择.
研究的目的:
- 在复发性SCLC患者中确定 lurbinectedin反应的预测生物标志物.
- 为了研究ISL1在SCLC生物学中的作用及其与 lurbinectedin敏感性的关联.
主要方法:
- 使用免疫组织化学 (IHC) 和双重质标记 (TMT) 标记的表达蛋白质学的预处理SCLC标本的分析.
- 在SCLC细胞系中通过敲击实验和RNA测序对候选生物标志物的功能验证.
- 生物标志物表达与治疗反应和DNA损伤诱导的相关性.
主要成果:
- SLFN11表达没有预测 lurbinectedin响应.
- 蛋白质组学发现了一个原始的神经内分泌路径,ISL1表达与对卢比内克丁的持续反应显著相关 (r = 0.65,P = 0.0351).
- 在没有亚型切换的情况下,ISL1"高"SCLC证明了对ISL1的细胞存活依赖性和对lurbinectedin诱导的DNA损伤的增强敏感性.
结论:
- ISL1代表了一种新的预测生物标志物,用于在一个独特的SCLC亚型中提高治疗效率.
- ISL1在功能上对SCLC细胞存活至关重要,其表达在治疗后减少.
- 计划进行前性研究,以验证ISL1作为SCLC中lurbinectedin治疗的预测生物标志物.
相关概念视频
Brick Durability, Strength, and Appearance
649
Brick durability, strength, and appearance are crucial factors in construction, influencing the choice of bricks for specific applications. The process of freeze-thaw, for instance, significantly affects brick durability. This phenomenon occurs when water absorbed by a brick expands as it freezes, potentially causing damage when it melts and refreezes. Bricks are graded for durability: SW-grade bricks are the most durable, offering high strength and low water absorption, followed by MW-grade...
649
Predicting Molecular Geometry
45.6K
VSEPR Theory for Determination of Electron Pair Geometries
45.6K
Lung Capacity
56.2K
The air in the lungs is measured in volumes and capacities. Lung volume measures reflect the amount of air taken in, released, or left over after a lung function, like a single inhalation. Lung capacity measures are sums of two or more lung volume measures.
56.2K
Adrenergic Receptors: ɑ Subtype
2.8K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
2.8K
Adrenergic Receptors: β Subtype
3.7K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
3.7K
Diabetes Mellitus: Overview and Type I Subtype
5.0K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
5.0K


